Excellent quarterly.
Low cashburn. Another MTA. Means another multinational chemical/pesticide company has chosen to spend big dollars furthering our R & D efforts. Zero cost to Bio-Gene.
So much going on in the background of Bio-Gene and our cashburn is minimal which is testimony to the company's platform technology strategy.
I expect at least 2 of those 8 ongoing MTA's to move to the next stage of development being evaluation partnerships before the next quarterly.
Can't wait for the BASF stored grain 3 month trial results. This is a pivotal result for me.
Ann: Appendix 4C - 31 March 2020, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.47M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 10/10/2024 (20 minute delay) ? |
| BGT (ASX) Chart |
Day chart unavailable